logo

For the Inventor, By the Inventor

Seattle, WA, United States of America

Sen-Itiroh Hakomori

This inventor holds 26 USPTO granted patents, plus 5 CIPO patents, primarily in Vaccine Development. Top assignees: The Biomembrane Institute, University of Washington, Oncomembrane, Inc.. Active years: 1991-2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sen-Itiroh Hakomori. Retrieved from https://idiyas.com/inventor/sen-itiroh-hakomori

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26

% Patents Active = 96.2

 

Average Co-Inventor Count = 3.1

ph-index = 10

Forward Citations = 298(Granted Patents)


Location History:

  • Mercr Island, WA (US) (1994 - 1996)
  • Seattle, WA (US) (1991 - 2009)

Company Filing History:

goldMedal18 out of 37 
 
The Biomembrane Institute
 patents
silverMedal4 out of 2,172 
 
University of Washington
 patents
bronzeMedal3 out of 5 
 
Oncomembrane, Inc.
 patents
4. 2 out of 309 
 
Fred Hutchinson Cancer Center
 patents
5. 1 out of 1 
 
Hyogo Medical College
 patent
6. 1 out of 19 
 
Otsuka America Pharmaceutical, Inc.
 patents
7. 1 out of 519 
 
Sloan-Kettering Institute for Cancer Research
 patents
where one patent can have more than one assignee

Years Active: 1991-2009

Loading Chart...
Loading Chart...
Areas of Expertise:
Chlamydia Oligosaccharides
Trimethylsphingosine Derivatives
Monoclonal Antibodies
Vaccine Development
Sphingosine-1-Phosphate
Apoptosis Treatment
Cell Motility Inhibition
Escherichia Coli Susceptibility
Oncofetal Fibronectin
Gangliosides
Immune Induction
Long-Chain Glycolipid
26 patents (USPTO):Explore Patents
1. 7517851 - Chlamydia oligosaccharides (2009-04-14),
2. 7053067 - [object Object] (2006-05-30),
3. 6130205 - Method for determining susceptibility to Escherichia coli urinary tract (2000-10-10),
4. 6031135 - Trimethylsphingosine derivatives (2000-02-29),
5. 5877167 - Method for inhibition of cell motility by sphingosine-1-phosphate and (1999-03-02),
6. 5747048 - Monoclonal antibodies and vaccine development directed to human (1998-05-05),
7. 5663404 - Sphingosine-1-phosphate essentially free of L-threo isomer (1997-09-02),
8. 5660834 - Monoclonal antibodies and vaccine development directed to human (1997-08-26),
9. 5627171 - Sphingosine-1-phosphate/trimethylsphingosine composition (1997-05-06),
10. 5583160 - Methylsphingosine used to treat apoptosis (1996-12-10),
11. 5500215 - Methods for the production of antibodies and induction of immune (1996-03-19),
12. 5421733 - Synthesis of Le.sup.x ; dimeric Le.sup.x (difucosyl Y.sub.2 ; III.sup.3 (1995-06-06),
13. 5391800 - Method for inhibition of cell motility by sphingosine-1-phosphate, its (1995-02-21),
14. 5389530 - Methods for the production of antibodies and induction of immune (1995-02-14),
15. 5374532 - Method for determining susceptibility to escherichia coli urinary tract (1994-12-20),

Title: Sen-Itiroh Hakomori: Innovator in Oligosaccharide Research

Introduction

Sen-Itiroh Hakomori is a prominent inventor based in Seattle, WA, who has made significant contributions to the field of oligosaccharide research. With an impressive portfolio of 26 patents, Hakomori has developed innovative solutions that enhance our understanding of biological interactions at the molecular level.

Latest Patents

Among his latest patents are notable works focused on Chlamydia oligosaccharides. One of these patents details the specific oligosaccharides that facilitate the attachment of the organism to host cells. This research has important implications for medical science, particularly in the development of treatments and preventive measures for Chlamydia infections.

Career Highlights

Hakomori has had an illustrious career, working with esteemed institutions such as The Biomembrane Institute and the University of Washington. His dedication to research and innovation has positioned him as a leading figure in his field, contributing valuable insights and advancements through his work.

Collaborations

Throughout his career, Hakomori has collaborated with talented professionals, including Yasuyuki Igarashi and Edward D Nudelman. These partnerships have enhanced his research and aided in pushing the boundaries of knowledge regarding oligosaccharides and their practical applications.

Conclusion

Sen-Itiroh Hakomori's work exemplifies the impact of innovative research in the scientific community. His extensive patent portfolio and collaborations reflect a commitment to advancing our understanding of critical biological processes. As a leading inventor in oligosaccharide research, Hakomori continues to inspire future innovations in this vital area of study.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…